Although global clinical trials are necessary to achieve enrollment goals within a reasonable timeframe, a vision and foresight to plan appropriately for the diversity of outcomes is also required. Some of these considerations are:
clinical trials going forward, we have to take into account the demographics of the potential enrollees so that the underlying foundation of the clinical trial is not jeopardized. New therapies, such as LCZ696 and ivabradine, will be utilized at different rates across the globe, which may influence outcomes in future trials (3, 4) . Methods need to be put in place to monitor disease severity, practice patterns, and the uptake of new therapies. Clinical trials that enroll large numbers of patients in countries such as Eastern Europe or Russia may find that the length of stay for their hospitalized heart failure patients is longer and that readmission rates at 30 days are lower while having a similar mortality rate. These factors may directly influence the event rates, the Although global clinical trials are necessary to achieve enrollment goals within a reasonable timeframe, a vision and foresight to plan appropriately for the diversity of outcomes is also required. Some of these considerations are:
1. The planning process should include the approximate percentage of recruitment by various continents, regions, and countries.
2. The expected variation event rates by region of the world should be considered.
The expected variation in baseline demographics
should be incorporated into the planning process. 
